| Market Cap | 1.02B | P/E | 112.64 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -9.84B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -22.00% |
| Sales | 23.34B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -17.00% |
| Dividend | N/A | Price/Book | 0.02 | EPS next 5Y | - | 52W High Chg | -46.00% |
| Recommedations | - | Quick Ratio | 3.85 | Shares Outstanding | 89.90M | 52W Low Chg | 47.00% |
| Insider Own | 9.44% | ROA | -4.74% | Shares Float | 66.02M | Beta | 0.65 |
| Inst Own | 49.82% | ROE | -14.94% | Shares Shorted/Prior | -/- | Price | 12.39 |
| Gross Margin | 72.71% | Profit Margin | -42.14% | Avg. Volume | 946 | Target Price | - |
| Oper. Margin | -7.13% | Earnings Date | Nov 8 | Volume | 400 | Change | -6.35% |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.